Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) has become the first drug to be approved by the US Food and Drug Administration (FDA) as a treatment for noncirrhotic nonalcoholic ...

The new medication, Madrigal Pharmaceuticals’ resmetirom ... and Madrigal must complete a post-approval study to verify the drug’s clinical benefit. “I believe this approval milestone ...

but US biotech Madrigal Pharma thinks it now has enough evidence for its drug resmetirom to support regulatory filings. The Massachusetts company has reported the results of the phase 3 MAESTRO ...

Devonian Health Group Inc. (“Devonian” or the “Company”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage corporation focused on developing unique solution ...

In March 2024, the US Food and Drug Administration (FDA) granted accelerated approval to Rezdiffra™ (resmetirom) in conjunction with diet and exercise for the treatment of adults with ...

Intercept Pharma’s obeticholic acid (OCA) – trying to become the first FDA-approved therapy for non ... was Madrigal Pharma’s resmetirom, which was able to reduce fibrosis and reduced ...

Rezdiffra (resmetirom), a once-daily, oral and liver-directed THR-β agonist. Rezdiffra gained the FDA’s accelerated approval in March 2024 for adult patients with nonalcoholic steatohepatitis (NASH).

If approved by your insurance company, getting a 90-day supply of the drug could help lower the cost. If you’re interested in this option, check with your doctor, pharmacist, or insurance provider.

Resmetirom, the first drug approved by US-FDA for the management of MASH, was used as positive control at an oral dose of 3.0 mg/kg once a day for 3 weeks. Thykamine™ administered orally ...